Nature: Drug Development: Chemical Brace discusses BioAxone’s lead drug Cethrin as one of the current spinal cord injury treatments with the potential to become “handy implements in the neurosurgeon’s kit.”
Forbes Magazine: The Forbes Magazine article To Walk Again hails Cethrin as one of the surprising research findings offering “the first real glimmer of hope that damaged spinal cords can be repaired.”
Reader’s Digest: The Reader’s Digest article Paralysis Could Be Reversible notes that “At long last, there may be hope for people paralyzed by spinal cord injuries”, explaining that BioAxone’s Cethrin “may reverse what was once considered to be permanent paralysis.”
Global TV: A spinal cord injury patient showing remarkable improvements after Cethrin treatment was interviewed on Global TV. Neurosurgeon Dr. Michael Fehlings comments on the promising reductions in paralysis seen in this patient and other participants in the Phase I/IIa Cethrin trial.
Windhover/Elsevier: BioAxone’s Cethrin was selected by Windhover and its advisors as one of the “Top 10 Neuroscience Projects to Watch.”
NeuroPerspective: The July/August 2011 issue of NeuroPerspective highlights the “striking” results of the Phase I/IIa Cethrin trial, commenting that “between preliminary evidence of impressive benefit, and Cethrin’s strong safety profile, this is an underappreciated program.”
The Toronto Star: A spinal cord injury patient demonstrating a remarkable recovery in mobility after receiving Cethrin treatment during the Phase I/IIa clinical trial was highlighted in an issue of the Toronto Star. Neurosurgeon Dr. Michael Fehlings comments on the “astonishing” rate of recovery in patients treated with Cethrin and the article emphasizes that Cethrin may help reverse paralysis after spinal cord injury.
FirstWord Pharma: An article announces the publication of Phase I/IIa Cethrin trial results in the Journal of Neurotrauma, noting “the potential of Cethrin to promote recovery of upper body movement in quadriplegic patients.”
Boston Herald: In an article highlighting the opening of BioAxone’s Cambridge office, the Boston Herald provides an overview of Cethrin as a neuroregenerative treatment in clinical development for spinal cord injury.
MassBio: The Massachusetts Biotechnology Council and Governer of Massachusetts welcome BioAxone to Cambridge, noting that the company’s development of Cethrin “is a source of hope for individuals suffering from traumatic spinal cord injuries.”
Spinal Connections: Spinal Connections, a publication by the Reeve-Irvine Research Center, provides an overview of the “very promising” results of the Phase I/IIa Cethrin trial, stating that “from the safety standpoint, the Phase I portion of the trial was a success” and “better yet, there was evidence that Cethrin improved function in people with cervical injuries.”
The Globe and Mail: The development of Cethrin as a treatment for spinal cord injury was hailed as a “success story” in an article about well-known spinal cord injury activist Rick Hansen.
R&D Directions: Cethrin named one of 100 Great Investigational Drugs by R&D Directions.